AchilliCPundirJRamanathanP, et al. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril2017; 107: 475–482. e415.
2.
ScottAHollowayDRymerJ, et al.The testosterone prescribing practice of BMS menopause specialists. Post Reprod Health2021; 27(2): 77–88.
3.
DavisSRBaberRPanayN, et al.Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab2019; 104(10): 4660–4666.
4.
DavisSRBaberRPanayN, et al.Response to letter to the editor: “global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab2020; 105(6): dgaa126.
5.
HamodaHPanayNPedderH, et al.The british menopause society & women’s health concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health2020; 26(4): 181–209.
6.
IslamRMBellRJGreenS, et al.Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol2019; 7(10): 754–766.
7.
MaclaranKPanayN. Managing low sexual desire in women. Women’s Health (LondEngl)2011; 7(5): 571–581.
8.
MaclaranKPanayN. The safety of postmenopausal testosterone therapy. Women’s Health (Lond Engl)2012; 8(3): 263–275.
PanayNMedical Advisory Council of the British Menopause Society. BMS - Consensus statement: Bioidentical HRT. Post Reprod Health2019; 25(2): 61–63.
11.
ParishSJSimonJADavisSR, et al.International society for the study of women’s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med2021; 18(5): 849–867.
